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Eighty-three symptom-free hemophiliacs were studied clinically, serologically, and 
by in vitro tests for cellular immunity in a geographical area in which AIDS has not 
yet been encountered despite the exclusive use of concentrates manufactured from 
American sources of plasma. Some patients showed the following abnormalites: 
lymphopenia (4 %), decreased T-helper/T-suppressor (Th/Ts) cell ratios (49 %), or 
both abnormalities (2%). Low Th/Ts were mostly due to absolute or, less frequently, 
relative increases in Ts cells. The prevalence rates for these abnormalites were the 
same in patients treated with factor VIII or factor IX concentrates. There was an 
association between the higher Ts and lower Th cells counts and the low ThlTs ratios 
and greater annual consumption of factor VIII and factor IX concentrates. These 
results support the view that protein load might be an important pathogenetic factor 
in lymphocyte abnormalities in symptom-free hemophiliacs. 
Key words: acquired immune deficiency syndrome, hemophilia, plasma concentrates, lymphocyte 
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INTRODUCTION 
Within the past few years a previously undescribed syndrome has been diag- 
nosed in more than 4,000 individuals in the United States and the morbidity rate is 
continuously increasing [ 1-51. This syndrome, called acquired immune deficiency 
syndrome (AIDS), is associated with a severe failure of the body’s immune sytem. 
Accordingly, the patient may develop rare malignancies and contract opportunistic 
infections, with an extremely high mortality rate. When reviewing the patient groups, 
about 75 % were found to be homosexual, 17 % intravenous drug users, 5 % Haitians, 
and 1 % are hemophiliacs [l-51. In hemophiliacs, the risk of AIDS seems to be related 
to treatment with concentrates, either by transmission of virus(es) contained in these 
preparations manufactured from very large plasma pools or by chronic exposure to 
multiple protein antigens and immune complexes that can depress the immune re- 
sponse and facilitate opportunistic infections [6] .  Neither of these mechanisms has yet 
been fully proven. The key laboratory abnormality in hemophiliacs (or other patient 
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groups) who have opportunistic infections is a marked decrease in circulating T- 
lymphocyte predominantly due to low T-helper lymphocytes and resulting in very 
low T-helper (h)/T-suppressor(s) ratios [ 1-61. However, several studies have also 
shown a high prevalence of abnormalities of lymphocyte subsets in symptomless 
hemophiliacs from the United States [7-141, the United Kingdom [ 15-17], Australia 
[18], and Austria [19]. In these patients, the low Th/Ts ratios are usually due to an 
absolute or relative augmentation of Ts rather than to low absolute Th numbers as in 
patients with overt AIDS. 
In Italy, hemophiliacs are treated either with the same commercial concentrates 
used by American hemophiliacs or with a concentrate manufactured in Austria from 
plasma mainly obtained from American donors by plasmapheresis. Therefore, they 
should theoretically be exposed to the same risk of contracting AIDS. A recent (1984) 
survey of 20 hemophilia centers made by the Italian Hemophilia Foundation has 
detected no case of opportunistic infection or malignancy among 2,350 of the 2,700 
hemophiliacs estimated to live in this country. Only three patients persistently had 
unexplained generalized lymphadenopathy, which is suspected to be prodromal of, or 
associated to, AIDS but the relationship is still unclear [14,19,20]. We thought that 
the peculiar situation of hemophilia care in Italy, a geographical area in which AIDS 
has not yet been seen in hemophiliacs despite patients’s exposure to USA sources of 
plasma, justified a study of T-lymphocyte subsets and other hematological parameters 
in an unselected group of 83 hemophiliacs coming for their annual check-ups at our 
center. We found that these patients, albeit asymptomatic, had a high prevalence of 
low Th/Ts ratios that were mainly due to an absolute increase in Ts cell counts; that 
the abnormality was present equally in patients treated with factor VIII or IX concen- 
trates, and was correlated with the amount of the concentrates used by the patient in 
the year preceding examination. 
PATIENTS AND METHODS 
Patients 
The study population consisted of 83 consecutive hemophiliacs (64 with hemo- 
philia A, 19 with hemophilia B) who came to the Hemophilia and Thrombosis Center 
for routine screening from March to June 1983. On each study day, healthy volunteer 
members of the laboratory staff and their parents and children were also studied, to 
have controls over the same age range (totaling 31). The clinical team filled in for 
both patients and controls detailed confidential questionnaires about personal and 
medical history, including drug exposure and sexual behaviour. The same doctors 
then examined all subjects, looking in particular for infection, lymphadenopathy, skin 
manifestations, or malignancy. All subjects were identified by numbers and the 
laboratory teams were unaware of clinical details. 
Information on type and intensity of replacement therapy in the past year (1982) 
was obtained from hospital records or from the patient’s records for those on home 
therapy (60% of all patients). All patients were managed on the basis of “on demand” 
replacement therapy, but three patients had had short courses (6-8 weeks) of prophy- 
lactic therapy for the management of chronic synovitis. In our center, the average 
annual consumption of factor VIII concentrates per patient in the year before the 
study (1982) was 28,000 I.U. for hemophilia A and 16,000 for hemophilia B. 
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Patients used exclusively commercial concentrates, manufactured from large 
plasma pools (for hemophilia A, Koate Cutter, Hemophil Hyland, and Kryobulin 
Immuno: for hemophilia B, Bebulin Immuno and Konyne Cutter). Amounts used in 
1982 resembled closely the amounts of treatment given in the previous years. The 
majority of patients used more than one commercial brand, making it impossible to 
divide them according to source of concentrates used. 
The 83 hemophiliacs were divided according to age, type and severity of 
hemophilia, intensity of treatment in the year before testing, positive or negative for 
HBV markers (HBsAg and anti-HBs) and serum levels of alanine transferase (ALT) 
(lower than 50 U/L, between 50 and 100 and higher than 100). (Table I). 
Methods 
The total white blood cell, lymphocyte, and platelet counts were determined 
with a Coulter S Plus counter. Total T, Th, and Ts phenotypes were defined by means 
of immunofluoresence with monoclonal antibodies OKT3, OKT4, and OKT8 (Ortho 
Diagnostic System, Milan). Fluorescent cells were counted by a fluorescence-acti- 
vated cell sorter (Spectrum, Ortho). We detected HBs Ag and anti-HBs by means of 
TABLE I. Clinical and Laboratory Variables for 83 
Asymptomatic Hemophiliacs 
No. Percent of total 
Age 
< 10 yr 21 25 
10-20 19 23 
21-30 20 24 
31-60 23 28 
Type of hemophilia 
Hemophilia A 
Hemophilia B 
Severity of hemophilia: 
Factor VIII < 1 % 
" " 1-5% 
" " > 5 %  
Factor IX < 1% 
1-5% 
> 5 %  
, I  , I  
I ,  I !  
Intensity of treatment 
Untreated 
< 20,000 U/yr 
>40,000 
20,000-40,OOO 
64 76 
19 24 
56 67 
I 1 
7 8 
14 17 
3 4 
2 3 
21 25 
24 29 
18 22 
20 24 
Markers for hepatitis B 
HBsAg + 3 4 
Anti-HBs and/or anti HBc + 61 73 
Alanine transferase 
< 50 U/L 57 69 
51-100 U/L 15 18 
> 100 U/L 11 13 
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radioimmunoassay (Austria I1 and AUSAB, Abbott Laboratories). We have defined 
as abnormal all values of blood cells and lymphocyte subsets that were outside the 
normal laboratory range established in this hospital. 
Statistical Tests 
Contingency tables were evaluated by the one-side Fisher exact test. Analysis 
of variance and the Wilcoxon rank sum test were used for comparing nonparametric 
variables in different groups; the Spearman rank test was used to check correlations 
between nonparametric variables. 
RESULTS 
The breakdown of patients according to demographic, clinical, and serological 
variables is shown in Table I. The different age groups were equally represented and 
the prevalence of hemophilia A over hemophilia B was similar to that expected from 
the general prevalence of the diseases. Patients could be divided into four groups of 
similar size according to the intensity of treatment, expressed as total units of factor 
VIII and IX concentrates infused in the year preceding examination (Wyr). There 
were 13 patients with mild or moderate hemophilia A or B and 8 patients with severe 
hemophilia who received no treatment in the preceding year in the untreated group. 
The prevalence of patients with anti-HBs (73%) is similar to that in our whole 
hemophilia population (go%), and was mainly ascribable to the treated hemophiliacs; 
the prevalence of mildly or grossly abnormal ALT is also similar to that of the whole 
population. 
Leukopenia (< 4.0 x 109/L) was seen in three (4%) of 83 asymptomatic 
hemophiliacs, thrombocytopenia ( < 150 x 109/L) in nine (11 %) and lymphopenia 
(< 1.2 X 109/L) in four ( 5 % ) .  Leukopenia and lymphopenia were very mild, the 
lowest counts being 3.9 and 0.9 x 109/L respectively; only one patient had moder- 
ately severe thrombocytopenia (33 x 109/L), the next value being 80 x 109/L. T 
lymphocytes (< 0.9 x 109/L) were low in six patients (7%); Th low (< 0.5 X lo9/ 
L), in ten patients (12%); Ts low (< 0.3 x 109/L), in one patient only; Ts high (< 
1.2 X 109/L), in 15 patients (18%); Th/Ts ratios low (< 1.0), in 41 patients (49%) 
(Figs. 1-3). Only one of the four patients with lymphopenia also had low Th count 
and Th/Ts ratio; six of the nine thrombocytopenic patients had low ratios; none of the 
three patients with leukopenia had a low ratio. There was an association between 
amount of concentrate used and abnormalites of lymphocyte subsets. Figure 1 shows 
that in healthy controls, untreated hemophiliacs, and hemophiliacs treated with < 
20,000 U/yr, Th mean values did not differ; Th, however, were significantly lower 
in the 20,000-40,OOO U and > 40,000 U treatment subgroups (P < 0.005), with no 
significant difference between the last two subgroups. The Ts counts were signifi- 
cantly higher than in controls or untreated hemophiliacs in all of the three subgroups 
of treated hemophiliacs (P < 0.001); in turn, the two subgroups of more intensively 
treated patients had significantly higher Ts values than hemophiliacs treated with 
<2O,OOO U, with no significant differences between them (Fig. 2). The ThlTs ratios 
(Fig. 3) were significantly lower in the two subgroups of more intensively treated 
patients than in controls, untreated hemophiliacs, or the <2O,OOO U treatment group 
(P < 0.01). There were no differences between treatment groups with respect to 
leukocyte, total lymphocyte, T-lymphocyte, or platelet counts (data not shown). 
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Fig. 1. OKT4 positive (helper) T-lymphocytes in healthy controls and patients with hemophilia A 
(circles) and B (triangles) according to total concentrate dose administed over the past year. The solid 
upper and lower lines indicate the normal range; the bars indicate the mean values for the different 
subgroups. 
There was a significant nonparametric correlation between concentrate usage 
for each patient and Th/Ts ratios (Spearman's rho = -0.68, P < 0.001) (Fig. 4) 
and, to a lesser extent, Th counts (rho = + 0.43, P < 0.01) and Ts counts (rho = 
Investigation of the interrelationship between lymphocyte abnormalites and 
other variables in the hemophiliac population did not reveal any significant association 
between abnormalities of the T-lymphocyte subsets (expressed as Th/Ts ratios lower 
than 1.0) and such other variables of the population as age, HBV markers, or ALT 
levels (Table 11) . We have also evaluated whether the type of concentrate used affected 
the prevalence rate of alterations of lymphocyte subsets. Since the group of patients 
with hemophilia B treated with factor IX concentrates was small, we have divided the 
patients into three other dosage subgroups; no treatment, < 20,000 and > 20,000 
U/yr. While this subdivision confirmed the association between concentrates con- 
sumption and lower ratios, there was no significant difference between factor VIII or 
IX users in the corresponding dosage subgroups (Table 11). 
-0.36, P < 0.01). 
DISCUSSION 
Our symptomless hemophiliacs showed a moderate frequency of abnormalities 
of T-lymphocyte subpopulations. Lymphopenia with low Th counts, the key lympho- 
cyte abnormality in AIDS, was seen in one patient only. We could demonstrate an 
absolute reduction in Th cell number in 12% of the patients, but in no instance was 
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Fig. 2. 
concentrate dose administered over the past year. Symbols as in Figure 1. 
the decrease very pronounced (Fig. 1). Low Th/Ts ratios were mainly due to absolute 
or relative increases in Ts cells, with normal T-lymphocyte counts. This pattern of 
abnormality is common in symptomless American [7-141 and Austrian [ 191 hemo- 
philiacs treated with the same commercial concentrates used by our patients, as well 
as in Australian [ 181 and Scottish [ 161 hemophiliacs treated exclusively with concen- 
trates made from plasma of unpaid donors. This pattern has also been observed by 
several investigators, who call it “Ts augmentation,” in healthy homosexual men in 
the United Kingdom and the United States [21-231. A common link between these 
situations is the likelihood that these categories of individuals are chronically exposed 
to parenteral contact with allogenic proteins and multiple infectious agents. Since 
increased numbers of Ts cells (which include cytotoxic cells) are also found in patients 
recovering from common viral infections (cytomegalovirus, Epstein-Barr virus, var- 
icella, herpes simplex) [24-261 this “abnormality” is probably really a normal 
response to the repeated challenge of immunoregulatory cells by antigen rather than 
indicative of risk to AIDS. 
The most important finding in our study was the clear-cut association between 
abnormalities of the T-lymphocyte subpopulations and the amount of concentrate used 
in the year preceding the blood testing. In hemophiliacs treated with less than 20,000 
U/yr, abnormalities were generally no more frequent and pronounced than in healthy 
controls or untreated hemophiliacs, whereas abnormalities were much more frequent 
and pronounced in hemophiliacs treated with annual dosages greater than 20,000 U. 
In addition to the higher overall prevalence of lymphocyte subset abnormalities in the 
groups of more intensively treated hemophiliacs, there was also a significant correla- 
tion between individual annual consumption of concentrates and the Th/Ts ratios, the 
OKT8 positive (suppressor) T-lymphocytes in healthy controls and patients according to total 
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Fig. 3. Ratio of OKT4 positive (helper) T-lymphocytes to OKT8 positive (suppressor) lymphocytes in 
healthy controls and patients according to total concentrate dose administered over past year. Symbols 
as in Figure 1. 
Fig. 4. Relationship to the T-helperlsuppressor cell ratio (OKT4-OKT8 ratio) to concentrate used over 
the past year. Spearman's rank test: rho = -0.68 (P < 0.001). Symbols are as in Figure 1. 
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TABLE 11. T-Helper/T-Suppressor Ratios in Hemophilic Subgroups 
No. Percent 
No. Mean f S.D. abnormal abnormal 
Controls 
Age 
all hemophiliacs 
< 10 yrs. 
10-20 yrs. 
21-30 yrs. 
> 30yrs. 
Amount of concentrate used 
All hemophiliacs 
Untreated 
> 20,000 Uiyr 
>40,000 
20,ooO-40,000 
Factor VIII concentrates 
users 
Untreated 
< 20,000 IU/yr 
> 20,000 IU/yr 
Factor IX concentrates 
users 
Untreated 
< 20,000 IU/yr 
> 20,000 IU/yr 
HBV markers 
All hemophiliacs 
HBsAg + ve 
HBsAg - ve 
anti-HBs + ve 
anti-HBs - ve 
All hemophiliacs 
< 50 U/L 
51-100 U/L 
> 1OoU/L 
ALT levels 
31 
21 
19 
20 
23 
21 
24 
18 
20 
15 
17 
32 
6 
7 
6 
3 
80 
61 
22 
57 
15 
11 
1.76 f 0.68 
1.12 f 0.54 
1.00 f 0.42 
1.02 f 0.66 
1.26 & 0.53 
1.41 f 0.33 
1.43 f 0.63 
0.73 f 0.33 
0.75 f 0.25 
1.38 f 0.33 
1.55 f 0.69 
0.77 & 0.29 
1.50 f 0.35 
1.14 f 0.35 
0.57 f 0.20 
0.93 f 0.74 
1.12 0.54 
0.97 f 0.47 
1.24 f 0.60 
1.14 +_ 0.53 
1.12 & 0.57 
0.82 + 0.60 
0 
11 
11 
13 
7 
0 
5 
11 
14 
1 
4 
28 
1 
1 
6 
2 
41 
38 
6 
29 
7 
7 
0 
52 
58 
65 
30 
0 
21 
61 
70 
7 
23 
88 
17 
17 
100 
66 
51 
62 
28 
51 
47 
64 
Th, and the Ts counts. It might well be, therefore, that the extent of the foreign 
protein load is the main determinant of the abnormalites observed in our hemophil- 
iacs, although admittedly greater exposure to viruses cannot be disregarded in more 
intensively treated patients. Surprisingly, the problem of the association between the 
amount of concentrate administered and lymphocyte abnormalities has not been 
already widely investigated in hemophiliacs. Only Lee et a1 [7] have found signifi- 
cantly lower Th/Ts ratios in 47 hemophilia A patients treated with >25,OOO U/yr 
than in 17 patients treated with ~25,000 U. Two other studies [7,8] of small groups 
were unable to find such correlations between concentrate consumption and lympho- 
cyte abnormalites; in other studies [ 14,19,20], there was a trend toward lower Th/Ts 
ratios with increasing concentrate consumption but the relationship was not statisti- 
cally significant, probably because of the small number of cases or excessive subdi- 
vision of the patients according to concentrate consumption. Unlike in some studies 
[8,10,17], but in agreement with others [ 141, another interesting finding in our study 
was that the fractionation method used in concentrate manufacturing was not an 
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important determinant of lymphocyte abnormalities because abnormal ratios were 
also seen in hemophilia B patients treated with factor IX concentrates, with a similar 
association between large annual consumption and more pronouced abnormalities. 
We cannot at present explain these different findings, but it must be emphasized again 
that the numbers of hemophilia B patients were usually very small [8-101 in the pre- 
vious studies and that only one group of investigators studied more than 20 patients [ 171. 
Abnormal lymphocyte subpopulations per se cannot yet be used for diagnostic 
evidence of AIDS or its prodrome; only by longitudinal studies of asymptomatic 
hemophiliacs with abnormal values can the relevance of such tests to AIDS risk be 
established. Therefore, we cannot recommend using less than 20,000 U/yr in an 
attempt to prevent AIDS solely on the basis of these data. We continue our present 
policy of giving to the patients all the factor they need, on demand, for treatment of 
hemorrhages and elective surgery. However, we avoid long-term prophylaxis in an 
attempt to prevent all hemorrhage because there is no proof that such prophylaxis 
results in better prevention of hemophiliac arthropathy, while it does result in much 
larger concentrate consumption. 
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